Procurement Summary
Country: USA
Summary: Generation and Fluorescent Formatting of Aptamers Targeting Antiretroviral Drugs Arvs for the Detection of Unreported Arv Use on Behalf of the Cdcs National Center for Hiv, Viral Hepatitis, Std, and T...
Deadline: 31 Jul 2026
Posting Date: 30 Jul 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 146197061
Document Ref. No.: CDC-7D301-NCHHSTP-0001
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Generation and Fluorescent Formatting of Aptamers Targeting Antiretroviral Drugs Arvs for the Detection of Unreported Arv Use on Behalf of the Cdcs National Center for Hiv, Viral Hepatitis, Std, and Tuberculosis Prevention Division of Hiv Prevention
This is a combined synopsis/solicitation for a sole-source requirement.
The Centers for Disease Control and Prevention (CDC) Office of Acquisition Services intends to award a sole source contract to Texas A&M University for services to provide generation and fluorescent formatting of aptamers targeting antiretroviral drugs (ARVs) for the detection of unreported ARV use on behalf of the CDC-s National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention Division of HIV Prevention.
Antiretroviral drugs (ARVs) are the foundation of HIV treatment and prevention. Detection of unreported ARV use is essential for surveillance, behavioral research, and blood safety monitoring. While liquid chromatography with tandem mass spectrometry (LC-MS-MS) remains the gold standard for ARV detection, it is costly, labor-intensive, and impractical for high-throughput or resource-limited settings. These constraints limit its scalability for high-throughput surveillance and preclude its use in many public health or resource-limited laboratory settings.
The Division of HIV Prevention Laboratory Branch (DHP LB) at the CDC is developing a high-throughput assay that leverages aptamer-based technologies and plate-based detection to enable efficient qualitative screening of ARVs that are priorities for surveillance and blood safety monitoring.
The anticipated period of performance for a two-year multi-year contract from 8/03/2026 through 8/13/2028.
The NAICS Code is: 541715 - Research and Development Laboratories or Services (except Biotechnology and Nanotechnology Research and Development)
The PSC is: AJ12 - General Science and Technology R&D Services
As indicated above, this contract action is for services for...
Notice ID: cdc-7d301-nchhstp-0001
Department/Ind. Agency: health and human services, department of
Sub-tier: centers for disease control and prevention
Office: cdc office of acquisition services
Product Service Code: aj12 - general science and technology r&d services; general science and technology; applied research
NAICS Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Inactive Dates: aug 15, 2026
Inactive Policy: 15 days after date offers due
Documents
Tender Notice